Bioventus (NASDAQ:BVS) Shares Up 5.1% – Time to Buy?

Shares of Bioventus Inc. (NASDAQ:BVS) shot up 5.1% during trading on Wednesday . The company traded as high as $8.59 and last traded at $8.52. 291,690 shares were traded during mid-day trading, a decline of 31% from the average session volume of 423,999 shares. The stock had previously closed at $8.11.

Wall Street Analyst Weigh In

A number of brokerages have commented on BVS. CJS Securities began coverage on Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Craig Hallum lifted their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Barrington Research restated an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research note on Friday, May 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.00.

Bioventus Stock Performance

The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The company has a 50-day moving average price of $9.62 and a 200-day moving average price of $8.56. The firm has a market capitalization of $726.80 million, a price-to-earnings ratio of 21.22, a P/E/G ratio of 1.10 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The firm had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities research analysts forecast that Bioventus Inc. will post 0.77 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the sale, the director owned 44,997 shares of the company’s stock, valued at $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 33.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bioventus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP raised its holdings in Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after purchasing an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after purchasing an additional 1,887 shares in the last quarter. Deutsche Bank AG raised its holdings in Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP raised its holdings in Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after purchasing an additional 3,909 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.